Pharmaceutical Contract Development and Manufacturing-EMEA Market Status and Trend Report 2013-2023
Report Summary
Pharmaceutical Contract Development and Manufacturing-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pharmaceutical Contract Development and Manufacturing industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Pharmaceutical Contract Development and Manufacturing 2013-2017, and development forecast 2018-2023
Main market players of Pharmaceutical Contract Development and Manufacturing in EMEA, with company and product introduction, position in the Pharmaceutical Contract Development and Manufacturing market
Market status and development trend of Pharmaceutical Contract Development and Manufacturing by types and applications
Cost and profit status of Pharmaceutical Contract Development and Manufacturing, and marketing status
Market growth drivers and challenges
The report segments the EMEA Pharmaceutical Contract Development and Manufacturing market as:
EMEA Pharmaceutical Contract Development and Manufacturing Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Pharmaceutical Contract Development and Manufacturing Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pharmaceutical Manufacturing Services
Biologics Manufacturing Services
Drug Development Services
EMEA Pharmaceutical Contract Development and Manufacturing Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Big Pharma
Small Pharma
Generic Pharma
CRO
EMEA Pharmaceutical Contract Development and Manufacturing Market: Players Segment Analysis (Company and Product introduction, Pharmaceutical Contract Development and Manufacturing Sales Volume, Revenue, Price and Gross Margin):
AbbVie Inc.
Aenova Group
Recipharm AB
Catalent, Inc.
Thermo Fisher Scientific Inc.
Lonza Group Ltd
Almac Group
FAMAR Health Care Services
Vetter Pharma International GMBH
Consort Medical plc
Siegfried Holding AG
Boehringer Ingelheim International GmbH
Evonik Industries AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Pharmaceutical Contract Development and Manufacturing-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pharmaceutical Contract Development and Manufacturing industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Pharmaceutical Contract Development and Manufacturing 2013-2017, and development forecast 2018-2023
Main market players of Pharmaceutical Contract Development and Manufacturing in EMEA, with company and product introduction, position in the Pharmaceutical Contract Development and Manufacturing market
Market status and development trend of Pharmaceutical Contract Development and Manufacturing by types and applications
Cost and profit status of Pharmaceutical Contract Development and Manufacturing, and marketing status
Market growth drivers and challenges
The report segments the EMEA Pharmaceutical Contract Development and Manufacturing market as:
EMEA Pharmaceutical Contract Development and Manufacturing Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Pharmaceutical Contract Development and Manufacturing Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pharmaceutical Manufacturing Services
Biologics Manufacturing Services
Drug Development Services
EMEA Pharmaceutical Contract Development and Manufacturing Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Big Pharma
Small Pharma
Generic Pharma
CRO
EMEA Pharmaceutical Contract Development and Manufacturing Market: Players Segment Analysis (Company and Product introduction, Pharmaceutical Contract Development and Manufacturing Sales Volume, Revenue, Price and Gross Margin):
AbbVie Inc.
Aenova Group
Recipharm AB
Catalent, Inc.
Thermo Fisher Scientific Inc.
Lonza Group Ltd
Almac Group
FAMAR Health Care Services
Vetter Pharma International GMBH
Consort Medical plc
Siegfried Holding AG
Boehringer Ingelheim International GmbH
Evonik Industries AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
1.1 Definition of Pharmaceutical Contract Development and Manufacturing in This Report
1.2 Commercial Types of Pharmaceutical Contract Development and Manufacturing
1.2.1 Pharmaceutical Manufacturing Services
1.2.2 Biologics Manufacturing Services
1.2.3 Drug Development Services
1.3 Downstream Application of Pharmaceutical Contract Development and Manufacturing
1.3.1 Big Pharma
1.3.2 Small Pharma
1.3.3 Generic Pharma
1.3.4 CRO
1.4 Development History of Pharmaceutical Contract Development and Manufacturing
1.5 Market Status and Trend of Pharmaceutical Contract Development and Manufacturing 2013-2023
1.5.1 EMEA Pharmaceutical Contract Development and Manufacturing Market Status and Trend 2013-2023
1.5.2 Regional Pharmaceutical Contract Development and Manufacturing Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Pharmaceutical Contract Development and Manufacturing in EMEA 2013-2017
2.2 Consumption Market of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.2.1 Consumption Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.2.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.3 Market Analysis of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.3.1 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Europe 2013-2017
2.3.2 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Middle East 2013-2017
2.3.3 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Africa 2013-2017
2.4 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA 2018-2023
2.4.1 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA 2018-2023
2.4.2 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
3.1.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Downstream Industry
4.2 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Major Countries
4.2.1 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Europe
4.2.2 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Middle East
4.2.3 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Africa
4.3 Market Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
5.1 EMEA Economy Situation and Trend Overview
5.2 Pharmaceutical Contract Development and Manufacturing Downstream Industry Situation and Trend Overview
CHAPTER 6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Major Players
6.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Major Players
6.3 Basic Information of Pharmaceutical Contract Development and Manufacturing by Major Players
6.3.1 Headquarters Location and Established Time of Pharmaceutical Contract Development and Manufacturing Major Players
6.3.2 Employees and Revenue Level of Pharmaceutical Contract Development and Manufacturing Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie Inc.
7.1.1 Company profile
7.1.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.1.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.2 Aenova Group
7.2.1 Company profile
7.2.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.2.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Aenova Group
7.3 Recipharm AB
7.3.1 Company profile
7.3.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.3.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Recipharm AB
7.4 Catalent, Inc.
7.4.1 Company profile
7.4.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.4.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Catalent, Inc.
7.5 Thermo Fisher Scientific Inc.
7.5.1 Company profile
7.5.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.5.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific Inc.
7.6 Lonza Group Ltd
7.6.1 Company profile
7.6.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.6.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Lonza Group Ltd
7.7 Almac Group
7.7.1 Company profile
7.7.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.7.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Almac Group
7.8 FAMAR Health Care Services
7.8.1 Company profile
7.8.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.8.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of FAMAR Health Care Services
7.9 Vetter Pharma International GMBH
7.9.1 Company profile
7.9.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.9.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Vetter Pharma International GMBH
7.10 Consort Medical plc
7.10.1 Company profile
7.10.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.10.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Consort Medical plc
7.11 Siegfried Holding AG
7.11.1 Company profile
7.11.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.11.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Siegfried Holding AG
7.12 Boehringer Ingelheim International GmbH
7.12.1 Company profile
7.12.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.12.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim International GmbH
7.13 Evonik Industries AG
7.13.1 Company profile
7.13.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.13.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Evonik Industries AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
8.1 Industry Chain of Pharmaceutical Contract Development and Manufacturing
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
9.1 Cost Structure Analysis of Pharmaceutical Contract Development and Manufacturing
9.2 Raw Materials Cost Analysis of Pharmaceutical Contract Development and Manufacturing
9.3 Labor Cost Analysis of Pharmaceutical Contract Development and Manufacturing
9.4 Manufacturing Expenses Analysis of Pharmaceutical Contract Development and Manufacturing
CHAPTER 10 MARKETING STATUS ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Pharmaceutical Contract Development and Manufacturing in This Report
1.2 Commercial Types of Pharmaceutical Contract Development and Manufacturing
1.2.1 Pharmaceutical Manufacturing Services
1.2.2 Biologics Manufacturing Services
1.2.3 Drug Development Services
1.3 Downstream Application of Pharmaceutical Contract Development and Manufacturing
1.3.1 Big Pharma
1.3.2 Small Pharma
1.3.3 Generic Pharma
1.3.4 CRO
1.4 Development History of Pharmaceutical Contract Development and Manufacturing
1.5 Market Status and Trend of Pharmaceutical Contract Development and Manufacturing 2013-2023
1.5.1 EMEA Pharmaceutical Contract Development and Manufacturing Market Status and Trend 2013-2023
1.5.2 Regional Pharmaceutical Contract Development and Manufacturing Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Pharmaceutical Contract Development and Manufacturing in EMEA 2013-2017
2.2 Consumption Market of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.2.1 Consumption Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.2.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.3 Market Analysis of Pharmaceutical Contract Development and Manufacturing in EMEA by Regions
2.3.1 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Europe 2013-2017
2.3.2 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Middle East 2013-2017
2.3.3 Market Analysis of Pharmaceutical Contract Development and Manufacturing in Africa 2013-2017
2.4 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA 2018-2023
2.4.1 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA 2018-2023
2.4.2 Market Development Forecast of Pharmaceutical Contract Development and Manufacturing by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
3.1.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Downstream Industry
4.2 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Major Countries
4.2.1 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Europe
4.2.2 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Middle East
4.2.3 Demand Volume of Pharmaceutical Contract Development and Manufacturing by Downstream Industry in Africa
4.3 Market Forecast of Pharmaceutical Contract Development and Manufacturing in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
5.1 EMEA Economy Situation and Trend Overview
5.2 Pharmaceutical Contract Development and Manufacturing Downstream Industry Situation and Trend Overview
CHAPTER 6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Pharmaceutical Contract Development and Manufacturing in EMEA by Major Players
6.2 Revenue of Pharmaceutical Contract Development and Manufacturing in EMEA by Major Players
6.3 Basic Information of Pharmaceutical Contract Development and Manufacturing by Major Players
6.3.1 Headquarters Location and Established Time of Pharmaceutical Contract Development and Manufacturing Major Players
6.3.2 Employees and Revenue Level of Pharmaceutical Contract Development and Manufacturing Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie Inc.
7.1.1 Company profile
7.1.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.1.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.2 Aenova Group
7.2.1 Company profile
7.2.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.2.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Aenova Group
7.3 Recipharm AB
7.3.1 Company profile
7.3.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.3.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Recipharm AB
7.4 Catalent, Inc.
7.4.1 Company profile
7.4.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.4.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Catalent, Inc.
7.5 Thermo Fisher Scientific Inc.
7.5.1 Company profile
7.5.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.5.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific Inc.
7.6 Lonza Group Ltd
7.6.1 Company profile
7.6.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.6.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Lonza Group Ltd
7.7 Almac Group
7.7.1 Company profile
7.7.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.7.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Almac Group
7.8 FAMAR Health Care Services
7.8.1 Company profile
7.8.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.8.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of FAMAR Health Care Services
7.9 Vetter Pharma International GMBH
7.9.1 Company profile
7.9.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.9.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Vetter Pharma International GMBH
7.10 Consort Medical plc
7.10.1 Company profile
7.10.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.10.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Consort Medical plc
7.11 Siegfried Holding AG
7.11.1 Company profile
7.11.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.11.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Siegfried Holding AG
7.12 Boehringer Ingelheim International GmbH
7.12.1 Company profile
7.12.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.12.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim International GmbH
7.13 Evonik Industries AG
7.13.1 Company profile
7.13.2 Representative Pharmaceutical Contract Development and Manufacturing Product
7.13.3 Pharmaceutical Contract Development and Manufacturing Sales, Revenue, Price and Gross Margin of Evonik Industries AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
8.1 Industry Chain of Pharmaceutical Contract Development and Manufacturing
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
9.1 Cost Structure Analysis of Pharmaceutical Contract Development and Manufacturing
9.2 Raw Materials Cost Analysis of Pharmaceutical Contract Development and Manufacturing
9.3 Labor Cost Analysis of Pharmaceutical Contract Development and Manufacturing
9.4 Manufacturing Expenses Analysis of Pharmaceutical Contract Development and Manufacturing
CHAPTER 10 MARKETING STATUS ANALYSIS OF PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
